Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Catching DDMAC's Eye: Leaving Out Risk Information Proves Risky Practice For ISTA

This article was originally published in The Pink Sheet Daily

Executive Summary

ISTA receives a second warning letter from FDA in just over a year for promotional material that omits risk information for its lead ophthalmic product.

You may also be interested in...



Safety Concerns Over Larger Bottle For ISTA's Bromday Could Impact Other Eye Drugs

FDA's Center for Drug Evaluation and Research refused to approve ISTA's sNDA for a larger fill size of the topical non-steroidal anti-inflammatory because it does not believe a single bottle should be used to dose drug in both eyes.

Safety Concerns Over Larger Bottle For ISTA's Bromday Could Impact Other Eye Drugs

FDA's Center for Drug Evaluation and Research refused to approve ISTA's sNDA for a larger fill size of the topical non-steroidal anti-inflammatory because it does not believe a single bottle should be used to dose drug in both eyes.

Vitrase Journal Ad Lacks Risk Information, FDA Says

The violative ad for the spreading agent omits warnings, the Division of Drug Marketing, Advertising & Communications states.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072580

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel